文献速递哮喘

痰液2型标志物可预测抗IL-5治疗的重度哮喘缓解

Sputum Type 2 Markers Could Predict Remission in Severe Asthma Treated With Anti-IL-5.
PubMed 文献 · Chest · 2023-02-03

该观察性研究纳入52例接受抗IL-5治疗的重度哮喘患者,在治疗前检测痰液2型标志物。1年后11例达到缓解,缓解组基线痰嗜酸性粒细胞、巨噬细胞、淋巴细胞计数更高,中性粒细胞百分比更低,且痰eotaxin-1、TSLP、IL-5、EPX和IgE蛋白水平更高。单因素回归显示男性、痰中性粒细胞百分比及eotaxin-1、IL-5、EPX是潜在预测因子。

要点

  • 痰液2型标志物可能预测抗IL-5治疗后重度哮喘的缓解。
  • 缓解组基线痰eotaxin-1、TSLP、IL-5、EPX和IgE水平更高。
  • 结果需在更大队列中验证。

核心结论

  • 痰液2型标志物似乎可能预测重度嗜酸性哮喘患者抗IL-5治疗后的缓解。

研究设计与样本

  • 观察性研究,纳入比利时Liege大学医院哮喘门诊的52例启动抗IL-5治疗的重度哮喘患者。

主要发现

  • 52例中11例在治疗1年后被归类为缓解。
  • 缓解组痰嗜酸性粒细胞、巨噬细胞和淋巴细胞计数更高,痰中性粒细胞百分比低于非缓解组。
  • 缓解组基线痰eotaxin-1、TSLP、IL-5、EPX和IgE蛋白水平高于非缓解组。
  • 单因素回归分析显示男性相比女性、痰中性粒细胞百分比、eotaxin-1、IL-5和EPX是缓解的潜在预测因子。

关键数值与推荐

  • 缓解定义为治疗1年后同时满足:无慢性口服糖皮质激素治疗;无急性加重;哮喘控制问卷评分<1.5或哮喘控制测试评分>19或两者兼有;FEV1≥80%预计值或FEV1改善≥10%或两者兼有;血嗜酸性粒细胞计数<300 cells/μL。

临床怎么用

  • 对于重度嗜酸性哮喘患者,治疗前痰液2型标志物(如eotaxin-1、TSLP、IL-5、EPX、IgE)可能有助于识别抗IL-5治疗后更可能达到缓解的患者。

局限性

  • 结果需要在更大队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Biotherapies targeting IL-5 allow a tangible improvement of asthma. However, all patients do not respond the same way to these treatments. Even if high blood eosinophil counts seem to be associated with a reduction in exacerbations with treatment targeting IL-5, we lack biomarkers for the prediction of remission after these very expensive treatments. RESEARCH QUESTION: Are there biomarkers of remission after therapy targeting IL-5 in the sputum of patients with severe eosinophilic asthma? STUDY DESIGN AND METHODS: This observational study included 52 patients with severe asthma initiated with anti-IL-5 therapy and recruited from the asthma clinic of the Centre Hospitalier Universitaire of Liege, Belgium. Remission was defined as patients who combined the following at 1 year after therapy: no chronic treatment with oral corticosteroids; no exacerbation; asthma control questionnaire score < 1.5, asthma control test score > 19, or both; FEV1 of ≥ 80% predicted, improvement of FEV1 of ≥ 10%, or both; and a blood eosinophil count < 300 cells/μL. Eosinophil peroxidase (EPX), IgE, IL-3, IL-4, IL-5, IL-13, IL-25, IL-33, granulocyte-macrophage colony-stimulating factor, thymic stromal lymphopoietin (TSLP), and eotaxin-1 levels were measured in the sputum of these patients before anti-IL-5 treatment. RESULTS: Among the 52 patients, 11 were classified as being in remission. These patients were characterized by higher sputum eosinophil, macrophage, and lymphocyte counts, whereas the sputum neutrophil percentage was lower than in the nonremission group. In addition, the sputum eotaxin-1, TSLP, IL-5, EPX, and IgE protein levels were higher at baseline in the remission group compared with the nonremission group. Univariate regression analysis revealed that male vs female sex, sputum neutrophil percentage, eotaxin-1, IL-5, and EPX were potential predictors of remission. INTERPRETATION: Sputum type 2 markers seemed to be potentially predictive of remission after anti-IL-5 therapy in a cohort of patients with severe eosinophilic asthma. These results need validation on a larger cohort.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Moermans, Brion, Bock, et al. Sputum Type 2 Markers Could Predict Remission in Severe Asthma Treated With Anti-IL-5. Chest. 2023. PMID: 36740095. doi:10.1016/j.chest.2023.01.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。